Auriga Downgrades Protalix BioTherapeutics (PLX) to Hold
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.39 -2.05%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 60
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 60
Join SI Premium – FREE
Auriga downgraded Protalix BioTherapeutics (NYSE: PLX) from Buy to Hold with a price target of $8.00.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.99 yesterday.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Woolworths Group Ltd (WOW:AU) to Underperform
- KeyBanc Downgrades Apple (AAPL) to Underweight
- Goldman Sachs Downgrades Ruijie Networks Co (SZ:301165) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
